ARCO vs. CAVA: Which Stock Is the Better Value Option? — Positive
ARCO CAVA Zacks Investment Research — January 12, 2026Investors interested in stocks from the Retail - Restaurants sector have probably already heard of Arcos Dorados (ARCO) and Cava Group (CAVA). But which of these two stocks is more attractive to value investors?
HSTM vs. SHOP: Which Stock Is the Better Value Option? — Positive
HSTM SHOP Zacks Investment Research — January 12, 2026Investors interested in stocks from the Internet - Services sector have probably already heard of HealthStream (HSTM) and Shopify (SHOP). But which of these two stocks presents investors with the better value opportunity right now?
TD vs. IBN: Which Stock Should Value Investors Buy Now? — Positive
IBN TD Zacks Investment Research — January 12, 2026Investors with an interest in Banks - Foreign stocks have likely encountered both Toronto-Dominion Bank (TD) and ICICI Bank Limited (IBN). But which of these two stocks is more attractive to value investors?
KHNGY or CHRW: Which Is the Better Value Stock Right Now? — Neutral
CHRW Zacks Investment Research — January 12, 2026Investors interested in Transportation - Services stocks are likely familiar with Kuehne & Nagel International Ag (KHNGY) and C.H. Robinson Worldwide (CHRW).
CLPBY vs. PEN: Which Stock Is the Better Value Option? — Neutral
CLPBY PEN Zacks Investment Research — January 12, 2026Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
FTRE vs. ACAD: Which Stock Is the Better Value Option? — Positive
ACAD FTRE Zacks Investment Research — January 12, 2026Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Fortrea Holdings Inc. (FTRE) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
COO or WST: Which Is the Better Value Stock Right Now? — Neutral
COO WST Zacks Investment Research — January 12, 2026Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either The Cooper Companies (COO) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
MWA vs. NDSN: Which Stock Is the Better Value Option? — Neutral
MWA NDSN Zacks Investment Research — January 12, 2026Investors looking for stocks in the Manufacturing - General Industrial sector might want to consider either Mueller Water Products (MWA) or Nordson (NDSN). But which of these two stocks offers value investors a better bang for their buck right now?
DG or ROST: Which Is the Better Value Stock Right Now? — Neutral
DG ROST Zacks Investment Research — January 12, 2026Investors interested in Retail - Discount Stores stocks are likely familiar with Dollar General (DG) and Ross Stores (ROST). But which of these two stocks offers value investors a better bang for their buck right now?
TRMB Surges 15% in a Year: How Should You Approach the Stock in 2026? — Positive
TRMB Zacks Investment Research — January 12, 2026Trimble expands its portfolio, Connect & Scale strategy and growing digital solutions, strengthening its position across segments.
Netflix vs. Disney: Which Streaming Giant Has an Edge Right Now? — Positive
DIS NFLX Zacks Investment Research — January 12, 2026NFLX touts strong revenue growth, ad-tier momentum and subscriber gains, but faces margin pressure and a premium valuation in a fierce streaming showdown.
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs — Negative
NVO Reuters — January 12, 2026Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives have captured a significant share of demand for obesity treatments.
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Fermi Inc. (FRMI) — Neutral
FRMI Newsfile Corp — January 12, 2026Philadelphia, Pennsylvania--(Newsfile Corp. - January 12, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI) ("Fermi" or the "Company") on behalf of investors who purchased or otherwise acquired Fermi securities during the period of October 1, 2025 through December 11, 2025 (the "Class Period"), including in the Company's initial public offering on October 1, 2025. Investor Deadline: Investors who purchased Fermi securities during the Class Period may, no later than March 6, 2026, seek to be appointed as a lead plaintiff representative of the class.
From Peru to Mexico: Is AVO's Supply Chain Its Strongest Asset? — Positive
AVO Zacks Investment Research — January 12, 2026Mission Produce's diversified supply chain from Peru to Mexico helps smooth seasonality, manage pricing volatility and deliver a consistent avocado supply.
Did an Outdated Procedure Cause Rivian's 20K R1 Vehicle Recall? — Neutral
RIVN Zacks Investment Research — January 12, 2026RIVN is recalling nearly 20,000 R1 vehicles after an outdated service procedure may have caused rear toe link issues.
Two Low-Cost Airlines Plan to Merge. Wall Street Likes the Deal. — Positive
ALGT SNCY Investopedia — January 12, 2026Investors see sunshine for Sun Country Airlines stock following news that it plans to merge with another ultra-low-cost carrier.
ServiceNow (NOW) stock could be a worthwhile investment at this time. Why? Because it offers high margins – indicative of pricing power and the ability to generate cash – at a discounted price.
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals — Positive
ABVX Seeking Alpha — January 12, 2026Abivax (ABVX) remains a Buy, driven by obefazimod's strong UC data and significant multi-billion dollar market potential. ABVX is a credible M&A target, with Eli Lilly and other pharma giants rumored as potential acquirers, but fundamentals—not acquisition hopes—should drive investment decisions. Key 2026 catalysts include Phase 3 UC maintenance topline data, potential NDA/MAA filings, and Phase 2B Crohn's disease results.
Tesla, Inc. faces severe headwinds, with declining production, deliveries, and market share both in the US and Europe. TSLA's Q4 2025 production fell 5.5% YoY, deliveries dropped 15.6%, and full-year volumes declined despite overall EV market growth. Competitive pressures, eroding margins, and negative public perception—especially around Elon Musk—are accelerating TSLA's market share collapse.
ARMN's Margins Expand Despite Rising Costs: Will the Momentum Sustain? — Positive
ARMN Zacks Investment Research — January 12, 2026Aris Mining's AISC climbs 6.6% in Q3 2025, but higher gold prices and volumes lift margins 42% year over year, keeping profitability resilient.
